Petition asks FDA to set opioid marketing ground rules

Share this article:
Petition asks FDA to set opioid marketing ground rules
Petition asks FDA to set opioid marketing ground rules

On its face, the latest salvo in the prescription opioid conflict has absolutely nothing to do with their widespread abuse. Instead, by taking on “overly broad indications” on labels in a drug category that includes pain medications such as Purdue Pharma's Oxycontin and Endo Pharmaceutical's Percocet, a citizen's petition could achieve a related end: regulating the way drugmakers market these products.

The 37 signatories are asking the FDA to change the labels for prescription opioids to indicate that they are for severe pain as opposed to moderate-to-severe pain. The petition also asks the FDA to cap daily doses at 100 mg of morphine for non-cancer related pain, and for the labels to limit daily use for non-cancer pain to 90 days.

Dr. Andrew Kolodny, president of Physicians for Responsible Opioid Prescribing, one of the signatories, told MM&M that putting a dose limit on labels would not impinge upon a doctor's ability to create a medication regimen, since doctors would still be free to override the 100-mg guideline. Adding a ceiling would bring this pain pill category in line with others. “There are far more benign medications that have an upper dose limit,” he said.
 
These possible work-arounds could make the proposed changes appear cosmetic, but Kolodny, who also chairs the psychiatry department at Maimonides Medical Center in Brooklyn, said that walling off what he says could be considered off-label uses would help doctors walk away from things like CME programming about the medications “with a better sense of the risks vs. the benefits,” in part because the modifications would put appropriate uses in focus. (The FDA recently ruled to keep training on proper use of long-acting opioids voluntary for physicians, but that companies must provide grants for CME activities.)

Today's labels “imply a determination by the FDA that they are safe and effective for long-term use," petitioners argue. "An increasing body of medical literature suggests that long-term use of opioids may be neither safe nor effective.” The FDA has said it will respond directly to the petitioners.

Changing the label and setting time and dose limits could mean some uses could no longer be characterized as safe. As such, the moves could have a direct impact on promotion. Two of the-top 25 advertisers in professional media in 2011 were marketers with opioids in their pain portfolios. Purdue, 12th on the list according to data from Kantar media, spent $8.8 million for ads in journals last year, while Endo, 23rd on the list, spent $4.4 million.

Not all of this money went to promote pain medications, but modifying the labels of these drugs will have an impact on the million-dollar conversations that surround them.

Kolodny said the drugs' risks include tolerance effects that cause patients to increase doses, hormonal interference, and the possibility of addiction, among others. “It's unclear how many people become addicted, but many physicians were taught that addiction was extremely rare, and we've found this extremely false,” he added.

Neither Purdue nor Endo were available for comment.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...